BioSpace5h
BMS Positions Breyanzi for Another Indication as LOE Woes Mount
Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...
Bristol Myers Squibb Sees Positive Results for Breyanzi in Lymphoma Trials
Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.
Bristol Myers announces results from Phase 2 TRANSCEND FL trial
Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...
FiercePharma6h
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...
Cure Today4h
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...